Ptc Therapeutics (PTCT) Short term Debt (2012 - 2026)

Ptc Therapeutics' Short term Debt history runs 12 years deep, the most recent figure standing at $305.0 million for Q1 2026.

• In Q1 2026, Short term Debt rose 22.88% year-over-year to $305.0 million; the TTM figure through Mar 2026 stood at $305.0 million (up 22.88% YoY), while the FY2025 annual figure was $286.6 million, up 11.17% from the prior year.
• Short term Debt was $305.0 million for Q1 2026 at Ptc Therapeutics, up from $286.6 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $305.0 million in Q1 2026 to a low of $69.9 million in Q1 2022.
• Historically, Short term Debt has averaged $190.2 million across 5 years, with a median of $227.1 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Short term Debt jumped 238.13% in 2022, then fell 29.72% in 2023.
• A 5-year view of Short term Debt shows it stood at $72.1 million in 2022, then surged by 169.32% to $194.3 million in 2023, then jumped by 32.68% to $257.8 million in 2024, then climbed by 11.17% to $286.6 million in 2025, then rose by 6.42% to $305.0 million in 2026.
• The last three Short term Debt figures came in at $305.0 million (Q1 2026), $286.6 million (Q4 2025), and $260.6 million (Q3 2025), per Business Quant data.